Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

As treatment for spinal muscular atrophy (SMA) has drastically improved over the last decade, so too have survival rates and the number of people with SMA living well into adulthood. | A new education ...

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan ...

A new treatment for malaria in babies and very small children has just been approved; we hear more about the drug expected to save many lives.

Switzerland’s medical products authority has granted the first approval for a malaria medicine designed for small infants, ...

Swissmedic gave a green light Tuesday for the medicine from Basel-based pharmaceutical company Novartis for treatment of ...

Switzerland's medical products authority has granted the first approval for a malaria medicine designed for small infants.

Novartis on Tuesday said it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...

Novartis said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...

Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto® (lutetium (177Lu) vipivotide tetraxetan injection) is publicly reimbursed in Quebec for ...